News | Computed Tomography (CT) | April 09, 2021

American Journal of Roentgenology: IV contrast-enhanced 2-millisievert CT comparable to conventional-dose CT for diagnosis of right colonic diverticulitis

IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)


April 9, 2021 — According to an open-access article in ARRS' American Journal of Roentgenology (AJR), IV contrast-enhanced 2-millisievert CT (2-mSv CT) is comparable to conventional-dose CT (CDCT) for the diagnosis of right colonic diverticulitis.

"By mitigating concern of missed diagnosis of right colonic diverticulitis, our results further support the use of low-dose CT for suspected appendicitis," wrote first author Hae Young Kim from the department of radiology at Korea's Seoul National University Bundang Hospital. "To our knowledge," Kim et al. maintained, "this is the first study to formally measure the diagnostic performance of CT for right colonic diverticulitis."

Kim and colleagues' large pragmatic randomized controlled trial data included 3,074 patients (1,672 women, 1,402 men) aged 15-44 years old (median, 28 years) from 20 hospitals, randomized into 2-mSv (n = 1,535) or CDCT (median, 7-mSv; n = 1,539) groups from December 2013 to August 2016. A total of 161 radiologists prospectively issued CT reports, suggesting alternative diagnoses in 976 (2-mSV CT) and 924 (CDCT) patients.

In the intention-to-treat analysis, the between-group differences were minute with narrow 95% confidence intervals for most endpoints related to right colonic diverticulitis: test-positives (0.2%; p = .93), test-negatives (0.5%; p = .67), sensitivity (0.0%; p > .99), and specificity (0.2%; p = .66). The characteristics and disposition of test-positive patients were similar between the two groups.

"We believe our results reflect what can be expected in real-word conditions, owing to the pragmatic nature of the trial design, whereby we tried to deliver the intervention with the actual resources used in daily clinical practice," the authors of this AJR article added.

For more information: www.arrs.org


Related Content

News | Magnetic Resonance Imaging (MRI)

April 27 2026 — SimonMed, one of the nation’s largest independent outpatient imaging providers, has announced the ...

Time May 04, 2026
arrow
News | Computed Tomography (CT)

April 23, 2026 — Royal Philips has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ...

Time April 30, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Radiology Business

April 28, 2026 — The American Society of Radiologic Technologists will award Life Member status to three longstanding ...

Time April 29, 2026
arrow
News | Imaging Software Development

April 28, 2026 — Avatar Medical has been granted FDA 510(k) clearance for Avatar Medical Vision, its software platform ...

Time April 28, 2026
arrow
News | Cardiac Imaging

April 28, 2026 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next ...

Time April 28, 2026
arrow
News | Radiology Business

April 24, 2026 — The 2026 vacancy rate for radiation therapists decreased to 11.4% and the vacancy rate for medical ...

Time April 24, 2026
arrow
News | Contrast Agents

April 23, 2026 — On April 23, GE HealthCare announced the first patient has been dosed in the international, multi ...

Time April 23, 2026
arrow
News | Artificial Intelligence

April 20, 2026 — DeepTek, provider of the Augmento platform and deepc, the company behind deepcOS, have introduced a ...

Time April 23, 2026
arrow
News | FDA

April 16, 2026 — Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral ...

Time April 20, 2026
arrow
Subscribe Now